NASDAQ
13.05.26 | 21:30
2,055 US-Dollar
+1,23 % +0,025
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS | 1 | Seeking Alpha | ||
| Fr | ALX Oncology: 100 % Ansprechrate in Studie bestätigt CD47-Strategie | 6 | Investing.com Deutsch | ||
| Fr | ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy | 3 | Investing.com | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Fr | ALX Oncology GAAP EPS of -$0.17 beats by $0.02 | 1 | Seeking Alpha | ||
| Fr | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 566 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| Fr | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| Fr | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| Do | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 195 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen | |
| 17.04. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 2 | GlobeNewswire (USA) | ||
| 13.04. | ALX Oncology names Jeff Knight as chief development officer | 1 | Investing.com | ||
| 13.04. | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | 232 | GlobeNewswire (Europe) | - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13... ► Artikel lesen | |
| 13.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Wells Fargo initiates ALX Oncology stock with overweight rating | 6 | Investing.com | ||
| 10.03. | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, Palantir, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment | |||
| 09.03. | ALX ONCOLOGY HOLDINGS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.02. | ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing | 1 | Seeking Alpha | ||
| 27.02. | ALX Oncology: Aktie fällt nach verfehlter Gewinnprognose für Q4 2025 | 2 | Investing.com Deutsch | ||
| 27.02. | ALX Oncology GAAP EPS of -$0.42 misses by $0.06 | 1 | Seeking Alpha | ||
| 27.02. | ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 1.458 | GlobeNewswire (Europe) | - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company... ► Artikel lesen | |
| 27.02. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 5 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| MODERNA | 43,070 | -5,06 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| NOVAVAX | 7,890 | -3,78 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,655 | +1,48 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| INOVIO PHARMACEUTICALS | 1,119 | -7,14 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,360 | +3,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,300 | -1,64 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| EDITAS MEDICINE | 2,480 | -0,80 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,450 | +0,91 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| SAREPTA THERAPEUTICS | 16,100 | -1,23 % | Sarepta tumbles as its gene therapy sales decline further | ||
| EXELIXIS | 43,500 | +3,22 % | TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook | ||
| HALOZYME THERAPEUTICS | 58,30 | -3,48 % | Halozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2026 Results And Reiterates 2026 Financial Guidance | Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026
Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,124 | +2,70 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| NEUROCRINE BIOSCIENCES | 136,00 | +2,45 % | Neurocrine Q1 2026 slides: dual growth engines drive 45% sales jump | ||
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,055 Euro und damit +1,23 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.